scholarly journals Empirical Models for Anatomical and Physiological Changes in a Human Mother and Fetus During Pregnancy and Gestation

2018 ◽  
Author(s):  
Dustin F. Kapraun ◽  
John F. Wambaugh ◽  
R. Woodrow Setzer ◽  
Richard S. Judson

ABSTRACTMany parameters treated as constants in traditional physiologically based pharmacokinetic models must be formulated as time-varying quantities when modeling pregnancy and gestation due to the dramatic physiological and anatomical changes that occur during this period. While several collections of empirical models for such parameters have been published, each has shortcomings. We sought to create a repository of empirical models for tissue volumes, blood flow rates, and other quantities that undergo substantial changes in a human mother and her fetus during the time between conception and birth, and to address deficiencies with similar, previously published repositories. We used maximum likelihood estimation to calibrate various models for the time-varying quantities of interest, and then used the Akaike information criterion to select an optimal model for each quantity. For quantities of interest for which time-course data were not available, we constructed composite models using percentages and/or models describing related quantities. In this way, we developed a comprehensive collection of formulae describing parameters essential for constructing a PBPK model of a human mother and her fetus throughout the approximately 40 weeks of pregnancy and gestation. We included models describing blood flow rates through various fetal blood routes that have no counterparts in adults. Our repository of mathematical models for anatomical and physiological quantities of interest provides a basis for PBPK models of human pregnancy and gestation, and as such, it can ultimately be used to support decision-making with respect to optimal pharmacological dosing and risk assessment for pregnant women and their developing fetuses. The views expressed in this article are those of the authors and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency.AUTHOR SUMMARYPhysiologically based pharmacokinetic modeling is a well-known technique for making predictions about internal time-course concentrations of a substance that has entered an organism. This tool is widely used in both pharmaceutical research and human health risk assessment because it harnesses one of the fundamental tenets of both pharmacology and toxicology: it is the concentrations of an active chemical that reach internal target tissues, rather than externally applied “doses”, that govern the extent of the response (whether beneficial or adverse). Constructing physiologically based pharmacokinetic models for pregnancy and gestation presents a considerable challenge because many of the required parameters (such as blood flow rates or tissue volumes) that are typically assumed to be constant in adult models or short-duration simulations cannot be assumed to be constant when modeling pregnancy. Here we present models, stated as functions of gestational age, for anatomical and physiological changes that occur in a human mother and fetus during pregnancy and gestation. We evaluated and selected models by applying a consistent statistical technique, and where possible, we compared results produced by our models to those produced by previously-published models. The collection of pregnancy parameter models presented here represents the most comprehensive such collection to date.

2021 ◽  
Vol 23 (4) ◽  
Author(s):  
Ke Xu Szeto ◽  
Maxime Le Merdy ◽  
Benjamin Dupont ◽  
Michael B. Bolger ◽  
Viera Lukacova

AbstractThe purpose of this study was to develop a physiologically based pharmacokinetic (PBPK) model predicting the pharmacokinetics (PK) of different compounds in pregnant subjects. This model considers the differences in tissue sizes, blood flow rates, enzyme expression levels, glomerular filtration rates, plasma protein binding, and other factors affected during pregnancy in both the maternal and fetal models. The PBPKPlus™ module in GastroPlus® was used to model the PK of cefuroxime and cefazolin. For both compounds, the model was first validated against PK data in healthy non-pregnant volunteers and then applied to predict pregnant groups PK. The model accurately described the PK in both non-pregnant and pregnant groups and explained well differences in the plasma concentration due to pregnancy. The fetal plasma and amniotic fluid concentrations were also predicted reasonably well at different stages of pregnancy. This work describes the use of a PBPK approach for drug development and demonstrates the ability to predict differences in PK in pregnant subjects and fetal exposure for compounds excreted renally. The prediction for pregnant groups is also improved when the model is calibrated with postpartum or non-pregnant female group if such data are available.


2016 ◽  
Vol 60 (8) ◽  
pp. 4860-4868
Author(s):  
Todd J. Zurlinden ◽  
Garrett J. Eppers ◽  
Brad Reisfeld

ABSTRACTRifapentine (RPT) is a rifamycin antimycobacterial and, as part of a combination therapy, is indicated for the treatment of pulmonary tuberculosis (TB) caused byMycobacterium tuberculosis. Although the results from a number of studies indicate that rifapentine has the potential to shorten treatment duration and enhance completion rates compared to other rifamycin agents utilized in antituberculosis drug regimens (i.e., regimens 1 to 4), its optimal dose and exposure in humans are unknown. To help inform such an optimization, a physiologically based pharmacokinetic (PBPK) model was developed to predict time course, tissue-specific concentrations of RPT and its active metabolite, 25-desacetyl rifapentine (dRPT), in humans after specified administration schedules for RPT. Starting with the development and verification of a PBPK model for rats, the model was extrapolated and then tested using human pharmacokinetic data. Testing and verification of the models included comparisons of predictions to experimental data in several rat tissues and time course RPT and dRPT plasma concentrations in humans from several single- and repeated-dosing studies. Finally, the model was used to predict RPT concentrations in the lung during the intensive and continuation phases of a current recommended TB treatment regimen. Based on these results, it is anticipated that the PBPK model developed in this study will be useful in evaluating dosing regimens for RPT and for characterizing tissue-level doses that could be predictors of problems related to efficacy or safety.


2015 ◽  
Vol 17 (5) ◽  
pp. 1268-1279 ◽  
Author(s):  
Helen Musther ◽  
Katherine L. Gill ◽  
Manoranjenni Chetty ◽  
Amin Rostami-Hodjegan ◽  
Malcolm Rowland ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document